Ron Yu

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n et al. · The Lancet Oncology · 2014 · 716 citations

Medicine, Oncology, Pharmacotherapy +16

Molecular Dynamics and Free Energy Studies on the Wild-type and Double Mutant HIV-1 Protease Complexed with Amprenavir and Two Amprenavir-Related Inhibitors:  Mechanism for Binding and Drug Resistance

Tingjun Hou, Ron Yu · Journal of Medicinal Chemistry · 2007 · 260 citations

Life Sciences, Biochemistry, Pharmacology +17

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

John A. Flygare, Maureen H. Beresini, Nageshwar Budha et al. · Journal of Medicinal Chemistry · 2012 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

Mallika Singh, Anthony Lima, Rafael Molina et al. · Nature Biotechnology · 2010 · 215 citations

Life Sciences, Genetics, Oncology +12

Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O⁶-Alkylating Agents in Human Glioblastomas

Markus Bredel, Claudia Bredel, Dejan Juric et al. · Journal of Clinical Oncology · 2005 · 134 citations · Full text

Medicine, Molecular Biology, Oncology +17